Influence of alpha-tocopherol, propolis and piperine on therapeutic potential of tiferron against beryllium induced toxic manifestations.

Satendra Kumar Nirala, Monika Bhadauria, Ramesh Mathur, Asha Mathur

Index: J. Appl. Toxicol. 28(1) , 44-54, (2008)

Full Text: HTML

Abstract

The therapeutic potential of the chelator tiferron (sodium-4,5-dihydroxy-1,3-benzene disulphonate; 300 mg kg(-1), i.p.) and adjuvants, i.e. alpha-tocopherol (25 mg kg(-1), p.o.), propolis (a honey-bee hive product; 200 mg kg(-1), p.o.) and piperine (10 mg kg(-1), p.o.) were evaluated individually and in combination against beryllium induced biochemical alterations and oxidative stress consequences. Female albino rats were exposed to beryllium nitrate (1 mg kg(-1), i.p.) daily for 28 days followed by treatment with the above mentioned therapeutic agents for 5 consecutive days. Administration of beryllium altered blood biochemical variables with significant depletion in hemoglobin, blood sugar, total serum protein, albumin and significant enhancement in the release of serum transaminases. A significantly increased lipid peroxidation and a decreased level of glutathione after beryllium exposure indicated oxidative stress in the liver and kidney. Beryllium exposure decreased total protein and glycogen contents, whereas triglycerides and cholesterol increased significantly in liver and kidney. Individual administration of all the four compounds showed significant therapeutic potential in reverse of some of the biochemical parameters mentioned above. Furthermore, the combination of tiferron with alpha-tocopherol, propolis or piperine, respectively, could reverse all the variables significantly more towards the control. None of the test compounds showed any significant change in choleretic activity (bile flow and bile solids), indicating that these compounds had no adverse effects at these dose levels. It was concluded that all the combinations of tiferron and adjuvants played a beneficial role in reducing beryllium induced systemic toxicity at relatively lower doses and the combination of tiferron and propolis showed a more pronounced therapeutic potential.(c) 2007 John Wiley & Sons, Ltd.